The Study to Evaluate JS001 in Patients With Advanced GC, ESCC, NPC, HNSCC

Conditions:   Gastric Adenocarcinoma;   Esophageal Squamous Cell Carcinoma;   Nasopharyngeal Carcinoma;   Head and Neck Squamous Cell Carcinoma
Interventions:   Biological: 3 mg/kg humanized anti-PD-1 mAb;   Biological: 10 mg/kg humanized anti-PD-1 mAb
Sponsor:   Shanghai Junshi Bioscience Co.,Ltd.
Not yet recruiting - verified September 2016

http://ift.tt/2dAA0KM